Stem cell transplant study seeks best way to prevent immune attack

NCT ID NCT01231412

Completed Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested different drug combinations to prevent graft-versus-host disease (GVHD) in 174 people with blood cancers receiving stem cells from an unrelated donor. GVHD is a serious side effect where donor cells attack the patient's body. The goal was to find which drug regimen works best to control this risk while still allowing the transplant to succeed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia aggressive B-cell non-Hodgkin lymphoma B-cell chronic lymphocytic leukemia diffuse large B-cell lymphoma hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm Hodgkins lymphoma indolent B-cell non-Hodgkin lymphoma Leukemia, Myelogenous, Chronic, BCR-ABL Positive mantle cell lymphoma myelodysplastic syndrome Myelodysplastic Syndromes Myeloproliferative Disorders myeloproliferative neoplasm plasma cell myeloma Precursor Cell Lymphoblastic Leukemia-Lymphoma prolymphocytic leukemia T-cell prolymphocytic leukemia Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA ACUTE MYELOID LEUKEMIA AGGRESSIVE NON-HODGKIN LYMPHOMA CHRONIC LYMPHOCYTIC LEUKEMIA DIFFUSE LARGE B-CELL LYMPHOMA HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM INDOLENT NON-HODGKIN LYMPHOMA MANTLE CELL LYMPHOMA MYELODYSPLASTIC SYNDROME MYELOPROLIFERATIVE NEOPLASM PROLYMPHOCYTIC LEUKEMIA RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA RECURRENT PLASMA CELL MYELOMA REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE REFRACTORY HODGKIN LYMPHOMA SMALL LYMPHOCYTIC LYMPHOMA T-CELL CHRONIC LYMPHOCYTIC LEUKEMIA WALDENSTROM MACROGLOBULINEMIA

Contacts and locations

Locations

Aarhus University Hospital

Aarhus, 8200, Denmark
Emory University/Winship Cancer Institute

Atlanta, Georgia, 30322, United States
Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, 98109, United States
Huntsman Cancer Institute/University of Utah

Salt Lake City, Utah, 84112, United States
Medizinische Univ Klinik Koln

Cologne, 50924, Germany
Presbyterian - Saint Lukes Medical Center - Health One

Denver, Colorado, 80218, United States
Rigshospitalet University Hospital

Copenhagen, 2100, Denmark
Universitaet Leipzig

Leipzig, D-04103, Germany
University of Colorado

Denver, Colorado, 80217-3364, United States
University of Tuebingen-Germany

Tübingen, D-72076, Germany
VA Puget Sound Health Care System

Seattle, Washington, 98101, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.